EWTX Company Profile and Key Details

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) closed at $43.39 USD, losing -$0.43 (-0.98%) from the previous close of $43.82. The stock is currently mid-range between its 52-week high and low $13.69 and $48.40. With a market capitalization of about $4.67 billion, Edgewise Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.28). Key stats such as the average daily volume over the past year has been around 1.32 million shares, volume is running light vs its 52-week average. Headquartered in Boulder, CO, Edgewise Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kevin Koch, the company employs approximately 127 people and listed since March 26, 2021. Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders.

Edgewise Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.56. This means the shares are trading above this model’s fair value.

EWTX has shown sold momentum, gaining 19.06% over the past week and 90.77% over the past quarter, though year-to-date performance is up 15.78%. Short-term trend indicators are bearishly aligned (SMA20 0.14%, SMA50 9.3%, SMA200 57.84%). The stock’s 14-day RSI is 53.52 (neutral), while the ATR of 1.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.79% below its high and over 179.81% above its low. Average 10-day trading volume of 997.64 thousand shares is below the 3-month average of 1.28 million, indicating normal recent market interest.

Edgewise Therapeutics, Inc. has 108.60 million shares outstanding. The public float is 74.26 million shares, elevated short interest at 12.76% of float. This equals 9.84 million shares. The short ratio is 9.73 days. Institutional investors hold 114.09% of the float. Insiders own 0.45%. OrbiMed Genesis GP LLC holds 13.50 million shares, Novo Holdings A/S has 6.07 million shares and Flynn James E has 3.93 million shares. Over the past six months, insider transactions show net selling. They sold 191.53 thousand shares across 12 transactions.

Edgewise Therapeutics, Inc. generated EPS of -$1.58 over the past year. Five-year average earnings growth is -49.0%. Wall Street analysts project EPS growth of -11.87% annually over the next five years. The latest quarter delivered EPS of -$0.53. The next quarter is forecast at -$0.43. Next year's EPS is expected at -$33.36. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $20.00. The high target offers 36.92% upside. The low target suggests -54.36% downside. The mean target is $44.47. This offers 1.48% upside. Edgewise Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 13.32%. The prior quarter beat by -8.0%. Over the last six quarters, Apple has recorded several small beats. These include -4.44% in May 08, 2025.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) shares are up 15.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Edgewise Therapeutics, Inc. trading at a premium to the broader market with a P/E of -23.73. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $37.81, suggesting -13.72% downside. Our AI forecast model points to short-term weakness (-3.04% over two weeks), a medium-term rise (53.7% over three months), and a longer-term gain (22.16% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Edgewise Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.04%, with price expected at $42.49 by September 22, 2026, within a range of $40.85 to $44.13 3-Month Outlook: Projected rise of 53.7%, reaching $67.35 by December 07, 2026, with a range of $65.77 to $69.02. 1-Year Outlook: Projected gain of 22.16%, with price at $53.53 by September 08, 2027, within a range of $51.14 to $56.65.

Edgewise Therapeutics, Inc. trades at a P/E ratio of -23.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 10.55 reflecting a rich premium to book value. The P/FCF stands at -29.59, also below market averages. Compared to sector medians, Edgewise Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.